Cathie's Ark LogoCathie's Ark
BEGIN TYPING TO SEARCH BY TICKER
Trading Floor Community IconFrom the Trading Floor:
ARKG Holdings/ARCT/
Arcturus Therapeutics Holdings Inc Logo

ARKG Holdings of Arcturus Therapeutics (ARCT) - Updated Daily

Lock IconJoin Premium Plan

Trades of ARCT Made In ARKG

Why do the number of shares of a company held in an ARK ETF go up or down even when no trades are reported?

The Bucket Report Icon
The Bucket ReportSubscribe to get all the important numbers from the financial markets delivered to your inbox every trading day 📫
Date
Direction
Shares
Fund Weight
Fund
November 30, 2021BUY14.000k0.01%ARKG
November 1, 2021BUY24.824k0.0153%ARKG
October 27, 2021BUY52.127k0.0322%ARKG
October 26, 2021BUY14.525k0.0089%ARKG
October 25, 2021BUY67.105k0.0416%ARKG

Key Statistics

🕵🏼Found In🏷Last Price
ARKG$27.38
⚖️Weighting🧢Market Cap
1.64%$722.15m
🏋🏿‍♂️Weight Rank In ARKG🧮Price to Sales
2258.43
🏋️‍♀️Weight Rank Across All Funds🌏Country
62🇺🇸United States
💳ARK Estimated Cost Average🎫ARK Ownership Percent
$26.239%
Description
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation.
Website
arcturusrx.com

Research Notes and Commentary for ARCT